Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Vyome Holdings, Inc. (HIND : NSDQ)

• Company Description    Vyome Therapeutics Inc. is a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases principally in the US. Vyome Therapeutics Inc., formerly known as ReShape Lifesciences Inc., is based in CAMBRIDGE, Mass. Number of Employees: 18

• Price / Volume Information    Yesterday's Closing Price: $2.06 Daily Weekly Monthly 20 Day Moving Average: 7,450 shares Shares Outstanding: 7.02 (millions) Market Capitalization: $14.46 (millions) Beta: 1.50 52 Week High: $7.77 52 Week Low: $1.75 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -4.63% -2.86% 12 Week -5.07% -7.01% Year To Date -40.12% -44.95%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL Harvard Square One Mifflin Place Suite 400 - Cambridge,MA 02138 USA ph: 973-832-8147 fax: - contact@vyometx.com http://www.vyometx.com

• General Corporate Information    Officers Venkat Nelabhotla - President and Chief Executive Officer Krishna K. Gupta - Chairman Robert Dickey IV - Interim Chief Financial Officer Stash Pomichter - Director Shiladitya Sengupta - Director Peer Information Vyome Holdings, Inc. (GSAC) Vyome Holdings, Inc. (CASIF) Vyome Holdings, Inc. (ALCD.) Vyome Holdings, Inc. (OMNN) Vyome Holdings, Inc. (CGPI.) Vyome Holdings, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 92943X104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/13/26 Share - Related Items Shares Outstanding: 7.02 Most Recent Split Date: 8.00 (0.25:1) Beta: 1.50 Market Capitalization: $14.46 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.98 Price/Cash Flow: - Price / Sales: 38.67 EPS Growth vs. Year Ago Period: 98.89% vs. Previous Quarter: 33.33% Sales Growth vs. Year Ago Period: -78.26% vs. Previous Quarter: 743.75% ROE 06/30/26 - -197.33 03/31/26 - -247.00 12/31/25 - -295.00 ROA 06/30/26 - -138.14 03/31/26 - -162.50 12/31/25 - -149.66 Current Ratio 06/30/26 - 4.37 03/31/26 - 4.27 12/31/25 - 1.99 Quick Ratio 06/30/26 - 4.37 03/31/26 - 4.27 12/31/25 - 1.99 Operating Margin 06/30/26 - -3,039.55 03/31/26 - -988.75 12/31/25 - -447.91 Net Margin 06/30/26 - -3,024.84 03/31/26 - -984.66 12/31/25 - -445.64 Pre-Tax Margin 06/30/26 - -3,097.87 03/31/26 - -829.97 12/31/25 - -3,274.38 Book Value 06/30/26 - 1.04 03/31/26 - 1.15 12/31/25 - 0.67 Inventory Turnover 06/30/26 - - 03/31/26 - 0.11 12/31/25 - 0.08 Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©